Lazard Asset Management LLC Neurocrine Biosciences Inc Transaction History

Lazard Asset Management LLC

  • $58.2 Billion
  • Q1 2025

A detailed history of Lazard Asset Management LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Lazard Asset Management LLC holds 56,782 shares of NBIX stock, worth $7.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
56,782
Previous 59,279 4.21%
Holding current value
$7.1 Million
Previous $8.09 Million 22.38%
% of portfolio
0.01%
Previous 0.01%

Shares

33 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 15, 2025
SELL
$107.22 - $153.29 $267,728 - $382,765
-2,497 Reduced 4.21%
56,782 $6.28 Million
Q4 2024

Feb 14, 2025
SELL
$111.62 - $139.44 $1.75 Million - $2.18 Million
-15,643 Reduced 20.88%
59,279 $8.09 Million
Q3 2024

Nov 14, 2024
BUY
$114.58 - $153.15 $1.55 Million - $2.07 Million
13,489 Added 21.96%
74,922 $8.63 Million
Q2 2024

Aug 14, 2024
BUY
$130.86 - $143.19 $798,769 - $874,031
6,104 Added 11.03%
61,433 $8.46 Million
Q1 2024

May 14, 2024
BUY
$130.4 - $143.74 $1.16 Million - $1.28 Million
8,884 Added 19.13%
55,329 $7.63 Million
Q4 2023

Feb 14, 2024
BUY
$106.07 - $132.76 $2.04 Million - $2.55 Million
19,192 Added 70.42%
46,445 $6.12 Million
Q3 2023

Nov 14, 2023
BUY
$94.02 - $117.1 $2.39 Million - $2.97 Million
25,393 Added 1365.22%
27,253 $3.07 Million
Q2 2023

Aug 14, 2023
SELL
$89.53 - $104.87 $3.86 Million - $4.52 Million
-43,127 Reduced 95.87%
1,860 $175,000
Q1 2023

May 15, 2023
BUY
$94.11 - $123.02 $3.84 Million - $5.01 Million
40,752 Added 962.27%
44,987 $4.55 Million
Q4 2022

Feb 14, 2023
BUY
$106.72 - $127.06 $323,575 - $385,245
3,032 Added 252.04%
4,235 $505,000
Q3 2022

Nov 14, 2022
BUY
$92.03 - $107.81 $40,309 - $47,220
438 Added 57.25%
1,203 $127,000
Q2 2022

Aug 09, 2022
SELL
$75.79 - $100.07 $1,970 - $2,601
-26 Reduced 3.29%
765 $74,000
Q1 2022

May 13, 2022
SELL
$72.45 - $94.81 $3.46 Million - $4.52 Million
-47,717 Reduced 98.37%
791 $74,000
Q4 2021

Feb 09, 2022
BUY
$79.65 - $106.22 $1.15 Million - $1.53 Million
14,394 Added 42.19%
48,508 $4.13 Million
Q3 2021

Nov 15, 2021
BUY
$86.18 - $99.03 $2.94 Million - $3.38 Million
34,114 New
34,114 $3.27 Million
Q2 2021

Aug 12, 2021
SELL
$89.43 - $102.27 $81,828 - $93,577
-915 Closed
0 $0
Q1 2021

May 14, 2021
SELL
$87.57 - $119.4 $6,392 - $8,716
-73 Reduced 7.39%
915 $88,000
Q4 2020

Feb 11, 2021
BUY
$86.91 - $108.33 $2,433 - $3,033
28 Added 2.92%
988 $94,000
Q3 2020

Nov 13, 2020
SELL
$96.16 - $135.15 $20,385 - $28,651
-212 Reduced 18.09%
960 $92,000
Q2 2020

Aug 13, 2020
SELL
$85.09 - $130.36 $54,542 - $83,560
-641 Reduced 35.36%
1,172 $142,000
Q1 2020

May 14, 2020
BUY
$75.11 - $113.76 $94,563 - $143,223
1,259 Added 227.26%
1,813 $156,000
Q4 2019

Feb 13, 2020
SELL
$86.8 - $118.57 $76,904 - $105,053
-886 Reduced 61.53%
554 $59,000
Q3 2019

Nov 14, 2019
BUY
$83.82 - $101.5 $28,498 - $34,510
340 Added 30.91%
1,440 $129,000
Q4 2018

Feb 13, 2019
BUY
$68.32 - $124.36 $75,151 - $136,796
1,100 New
1,100 $78,000
Q3 2018

Nov 13, 2018
SELL
$98.88 - $125.85 $1.04 Million - $1.33 Million
-10,534 Closed
0 $0
Q2 2018

Aug 13, 2018
SELL
$75.3 - $105.99 $163,099 - $229,574
-2,166 Reduced 17.06%
10,534 $1.03 Million
Q1 2017

Aug 13, 2019
SELL
N/A
-1,500 Reduced 10.56%
12,700 $549,000
Q4 2016

Jul 30, 2019
SELL
N/A
-34,443 Reduced 70.81%
14,200 $549,000
Q3 2016

Aug 07, 2019
SELL
N/A
-19,041 Reduced 28.13%
48,643 $2.46 Million
Q2 2016

Jul 29, 2019
BUY
N/A
64,329 Added 1917.41%
67,684 $3.08 Million
Q4 2015

Jul 24, 2019
SELL
N/A
-2,525 Reduced 42.94%
3,355 $189,000
Q3 2015

Jul 15, 2019
BUY
N/A
1,490 Added 33.94%
5,880 $233,000
Q2 2015

Jul 08, 2019
BUY
N/A
4,390
4,390 $209,000

Others Institutions Holding NBIX

# of Institutions
649
Shares Held
97.1M
Call Options Held
749K
Put Options Held
553K
View Full List

About NEUROCRINE BIOSCIENCES INC

NBIX Quotes by TradingView
  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Lazard Asset Management LLC Portfolio

Follow Lazard Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email